[1]李疏凤,王帅,李婷婷,等.多重酪氨酸激酶受体抑制剂decorin对高糖低氧条件下血-视网膜内屏障的保护作用及机制研究[J].眼科新进展,2017,37(6):501-505.[doi:10.13389/j.cnki.rao.2017.0127]
　LI Shu-Feng,WANG Shuai,LI Ting-Ting,et al.Protective effects of decorin on blood-retinal barrier function under high-glucose plus hypoxia conditions[J].Recent Advances in Ophthalmology,2017,37(6):501-505.[doi:10.13389/j.cnki.rao.2017.0127]
点击复制

多重酪氨酸激酶受体抑制剂decorin对高糖低氧条件下血-视网膜内屏障的保护作用及机制研究/HTML
分享到：

《眼科新进展》[ISSN:1003-5141/CN:41-1105/R]

卷:
37卷
期数:
2017年6期
页码:
501-505
栏目:
实验研究
出版日期:
2017-06-05

文章信息/Info

Title:
Protective effects of decorin on blood-retinal barrier function under high-glucose plus hypoxia conditions
作者:
李疏凤; 王帅; 李婷婷; 杜珊珊; 吴强
200233　上海市，上海交通大学附属第六人民医院眼科（李疏凤，李婷婷，吴强）；450052　河南省郑州市，郑州大学第一附属医院眼科（王帅，杜珊珊）
Author(s):
LI Shu-Feng; WANG Shuai; LI Ting-Ting; DU Shan-Shan; WU Qiang
Department of Ophthalmology，Shanghai Jiaotong University Affiliated Sixth People’s Hospital（LI Shu-Feng，LI Ting-Ting，WU Qiang），Shanghai 200233，China；Department of Ophthalmology，the First Affiliated Hospital of Zhengzhou University（WANG Shuai，DU Shan-Shan），Zhengzhou 450052，Henan Province，China
关键词:
核心蛋白多糖; 血-视网膜屏障; 糖尿病视网膜病变; p38丝裂原活化蛋白激酶
Keywords:
decorin; blood-retinal barrier; diabetic retinopathy; p38 mitogen-activated protein kinase
分类号:
R774
DOI:
10.13389/j.cnki.rao.2017.0127
文献标志码:
A
摘要:
目的　研究核心蛋白多糖（decorin）对高糖低氧条件下血-视网膜内屏障的保护作用及机制。方法　培养人脐静脉内皮细胞，采用细胞计数试剂盒检测不同浓度decorin对人脐静脉内皮细胞存活率的影响；高糖低氧条件下（25 mmol·L-1右旋葡萄糖+100 μmol·L-1 CoCl2）孵育人脐静脉内皮细胞，通过ELISA检测不同浓度decorin处理后，不同时间点人脐静脉内皮细胞分泌血管内皮生长因子水平。将细胞分为正常对照组（5.5 mmol·L-1右旋葡萄糖）、高糖低氧组（25 mmol·L-1右旋葡萄糖+100 μmol·L-1 CoCl2）、甘露醇对照组（5.5 mmol·L-1右旋葡萄糖+19.5 mmol·L-1甘露醇）及decorin处理组（25 mmol·L-1右旋葡萄糖+100 μmol·L-1 CoCl2+100 nmol·L-1 decorin），通过检测跨内皮细胞电阻（transendothelial electrical resistance，TER）、异硫氰酸荧光素标记的右旋糖酐（fluorescein isothiocyanate，FITC-dextran）的渗漏率来评估单层人脐静脉内皮细胞的屏障功能；Western blotting检测内皮细胞间紧密连接蛋白（claudin-5、occludin、ZO-1）及p38 丝裂原活化蛋白激酶（p38 mitogen-activated protein kinase，p38 MAPK）的磷酸化水平。结果　细胞计数试剂盒检测发现，10 nmol·L-1、50 nmol·L-1、100 nmol·L-1、200 nmol·L-1 decorin处理人脐静脉内皮细胞 24 h后，各组人脐静脉内皮细胞的存活率均大于90%，差异无统计学意义（均为P>0.05）。在接种后14 d，单层人脐静脉内皮细胞的TER达到最大值且趋于稳定为（170.67±9.07）Ω。与正常对照组比较，高糖低氧处理48 h后，高糖低氧组的TER显著降低至（97.33±6.11）Ω，而decorin组的TER能够维持在（157.67±11.72）Ω，与高糖低氧组相比，差异有统计学意义（P<0.05）。高糖低氧处理48 h后，高糖低氧组FITC-dextran的渗透性明显增加，488 nm处的吸光度值为正常对照组的（2.12±0.07）倍（P< 0.05）。加入100 nmol·L-1 的decorin处理后，FITC-dextran的渗透性明显减少，吸光度值是正常对照组的（1.16±0.03）倍，与高糖低氧组的差异有统计学意义（P<0.05）。高糖低氧处理48 h后，高糖低氧组紧密连接蛋白claudin-5表达量为0.38±0.05、occludin为0.43±0.02及ZO-1为0.25±0.02与正常对照组表达量0.72±0.05、0.90±0.01和0.75±0.02相比，差异均有统计学意义（均为P<0.05）。decorin组claudin-5、occludin及ZO-1表达量分别为0.65±0.08、0.87±0.03和0.60±0.01，与高糖低氧组相比，差异均有统计学意义（均为P<0.05）。高糖低氧组p-p38 MAPK/p38 MAPK的比值增加，为 0.88±0.02，而decorin组p-p38 MAPK/p38 MAPK的比值（0.58±0.04）接近正常对照组水平（0.56±0.02），与高糖低氧组比较，差异有统计学意义（P<0.05）。结论　decorin能够保护高糖低氧条件下单层人脐静脉内皮细胞的屏障功能并下调p38 MAPK的表达水平，是治疗糖尿病视网膜病变的可能药物。
Abstract:
Objective　To evaluate the protective effects of decorin on the inner blood-retinal barrier function under high-glucose plus hypoxia conditions,and explore its potential mechanism.Methods　The human umbilical vein endothelial cells (HUVEC) were cultured,and the effect of decorin with different concentrations on HUVEC viability was determined by using the cell counting kit-8 assay (CCK-8).At different hours after incubation under high-glucose plus hypoxia conditions (25 mmol·L-1 D-glucose+100 μmol·L-1 CoCl2),the suppression effects of various concentrations of decorin on the vascular endothelial growth factor (VEGF) expression of HUVEC was detected by enzyme-linked immunosorbent assay(ELISA).HUVEC were divided into normal control group (5.5 mmol·L-1 D-glucose),high-glucose plus hypoxia group (25 mmol·L-1 D-glucose+100 μmol·L-1 CoCl2),mannitol control group(5.5 mmol·L-1 D-glucose+19.5 mmol·L-1 mannitol ) and decorin treatment group (25 mmol·L-1 D-glucose+100 μmol·L-1 CoCl2+100 nmol·L-1 decorin).HUVEC barrier function was evaluated by detecting transepithelial electrical resistance (TER) and permeability of fluorescein isothiocyanate-dextran (FITC-dextran).The content of tight junction proteins (claudin-5,occludin,and ZO-1) and p38 mitogen-activated protein kinase (MAPK) phosphorylation were examined by Western blotting.Results　According to the results of CCK-8,the survival rates of HUVEC in all groups were more than 90%,different concentrations of decorin showed no significant effect on HUVEC survival (all P>0.05).According to the results of CCK-8 and ELISA,the stimulation of hypoxia for 48 hours and 100 nmol·L-1 decorin was taken as the condition of further experiment.At 14 days,TER of HUVEC reached its peak of (170.67±9.07)Ω.TER of high-glucose plus hypoxia group (97.33±6.11)Ω was significantly lower than that of decorin treatment group (157.67±11.72)Ω(P<0.05).The FITC-dextran permeability of high-glucose plus hypoxia group increased to (2.12±0.07) times of normal control group(P<0.05).Decorin reversed this effect to (1.16±0.03) times of normal control group (P<0.05).The expression of claudin-5,occludin and ZO-1 in high-glucose plus hypoxia group were 0.38±0.05,0.43±0.02,0.25±0.02,compared to the normal control group (0.72±0.05,0.90±0.01,0.75±0.02),there were statistical differences (all P<0.05).The expression of claudin-5,occludin and ZO-1 in decorin treatment group were 0.65±0.08,0.87±0.03,0.60±0.01,there were statistical differences compared with high-glucose plus hypoxia group (all P<0.05).The ration of p-p38 MAPK/p38 MAPK in high-glucose plus hypoxia group (0.88±0.02) was increased,while the decorin treatment group (0.58±0.04) reached the level of the normal control group (0.56±0.02),there was statistical difference compared with high-glucose plus hypoxia group (P<0.05).Conclusion　Decorin can protect the HUVEC barrier function under high-glucose plus hypoxia conditions and inhibit the activation of p38 MAPK signaling pathway.So it may be used to treat diabetic retinopathy.

参考文献/References:

［1］　KLAASSEN I，VAN NOORDEN CJ，SCHLINGEMANN RO.Molecular basis of the inner blood-retinal barrier and its breakdown in diabetic macular edema and other pathological conditions［J］.Prog Retin Eye Res，2013，34（5）：19-48.
［2］　WANG S，DU S，WU Q，HU J，LI T.Decorin prevents retinal pigment epithelial barrier breakdown under diabetic conditions by suppressing p38 mapk activation［J］.Invest Ophthalmol Vis Sci，2015，56 （5）：2971-2979.
［3］　IACOBAZZI D，GARAEVA I，ALBERTARIO A，CHERIF M，ANGELINI GD，CAPUTO M，et al.Protein phosphatase 1 beta is modulated by chronic hypoxia and involved in the angiogenic endothelial cell migration［J］.Cell Physiol Biochem，2015，36 （1）：384-394.
［4］　KURICOVA K，PACAL L，SOUPAL J，PRAZNY M，KANKOVA K.Effect of glucose variability on pathways associated with glucotoxicity in diabetes：Evaluation of a novel in vitro experimental approach［J］.Diabetes Res Clin Pract，2016，114：1-8.
［5］　FELINSKI EA，ANTONETTI DA.Glucocorticoid regulation of endothelial cell tight junction gene expression：novel treatments for diabetic retinopathy［J］.Curr Eye Res，2005，30 （11）：949-957.
［6］　KERNT M，THIELE S，LIEGL RG，KERNT B，EIBL K，HARITOGLOU C，et al.Axitinib modulates hypoxia-induced blood-retina barrier permeability and expression of growth factors［J］.Growth Factors，2012，30 （1）：49-61.
［7］　IOZZO RV，SANDERSON RD.Proteoglycans in cancer biology，tumour microenvironment and angiogenesis［J］.J Cell Mol Med，2011，15 （5）：1013-1031.
［8］　DU S，WANG S，WU Q，HU J，LI T.Decorin inhibits angiogenic potential of choroid-retinal endothelial cells by downregulating hypoxia-induced Met，Rac1，HIF-1 alpha and VEGF expression in cocultured retinal pigment epithelial cells［J］.Exp Eye Res，2013，116：151-160.
［9］　KIM JH，KIM JH，LEE YM，AHN EM，KIM KW，YU YS.Decursin inhibits VEGF-mediated inner blood-retinal barrier breakdown by suppression of VEGFR-2 activation［J］.J Cereb Blood Flow Metab，2009，29 （9）：1559-1567.
［10］　ZHANG C，WANG H，NIE J，WANG F.Protective factors in diabetic retinopathy：focus on blood-retinal barrier［J］.Discov Med，2014，18 （98）：105-112.
［11］　STEWART EA，SAKER S，AMOAKU WM.Dexamethasone reverses the effects of high glucose on human retinal endothelial cell permeability and proliferation in vitro［J］.Exp Eye Res，2016，151：75-81.
［12］　FAN L，YAN H.FTY720 attenuates retinal inflammation and protects blood-retinal barrier in diabetic rats［J］.Invest Ophthalmol Vis Sci，2016，57 （3）：1254-1263.
［13］　HUANG J，LI X，LI M，LI S，XIAO W，CHEN X，et al.Effects of intravitreal injection of KH902，a vascular endothelial growth factor receptor decoy，on the retinas of streptozotocin-induced diabetic rats［J］.Diabetes Obes Metab，2012，14 （7）：644-653.
［14］　DU Y，TANG J，LI G，BERTI-MATTERA L，LEE CA，BARTKOWSKI D，et al.Effects of p38 MAPK inhibition on early stages of diabetic retinopathy and sensory nerve function［J］.Invest Ophthalmol Vis Sci，2010，51 （4）：2158-2164.
［15］　ADACHI T，TERAMACHI M，YASUDA H，KAMIYA T，HARA H.Contribution of p38 MAPK，NF-kappaB and glucocorticoid signaling pathways to ER stress-induced increase in retinal endothelial permeability［J］.Arch Biochem Biophys，2012，520 （1）：30-35.
［16］　SCOTT RA，PANITCH A.decorin mimic regulates platelet-derived growth factor and interferon-gamma stimulation of vascular smooth muscle cells［J］.Biomacromolecules，2014，15（6）：2090-2103.
［17］　YAN W，WANG P，ZHAO CX，TANG J，XIAO X，WANG DW.decorin gene delivery inhibits cardiac fibrosis in spontaneously hypertensive rats by modulation of transforming growth factor-beta/Smad and p38 mitogen-activated protein kinase signaling pathways［J］.Hum Gene Ther，2009，20 （10）：1190-1200.
［18］　RUNKLE EA，MU D.Tight junction proteins：from barrier to tumorigenesis［J］.Cancer Letters，2013，337 （1）：41-48.
［19］　FARJO KM，FARJO RA，HALSEY S，MOISEYEV G，MA JX.Retinol-binding protein 4 induces inflammation in human endothelial cells by an NADPH oxidase- and nuclear factor kappa B-dependent and retinol-independent mechanism［J］.Mol Cell Biol，2012，32 （24）：5103-5115.
［20］　DAL MONTE M，REZZOLA S，CAMMALLERI M，BELLERI M，LOCRI F，MORBIDELLI L，et al.Antiangiogenic effectiveness of the urokinase receptor-derived peptide uparant in a model of oxygen-induced retinopathy［J］.Invest Ophthalmol Vis Sci，2015，56 （4）：2392-2407.
［21］　WANG L，LUO H，CHEN X，JIANG Y，HUANG Q.Functional characterization of S100 A8 and S100 A9 in altering monolayer permeability of human umbilical endothelial cells［J］.PLoS One，2014，9 （3）：e90472.

相似文献/References:

[1]李艳 李筱荣 袁佳琴 潘斌.糖尿病大鼠视网膜中VEGF、PEDF的表达与血-视网膜屏障损伤[J].眼科新进展,2013,33(1):000.
[2]沈强 张学东.糖尿病黄斑水肿的发病机制及治疗进展[J].眼科新进展,2012,32(2):000.
[3]肖慧珍 彭绍民.紧密连接在视网膜病理生理中的作用[J].眼科新进展,2013,33(5):000.
[4]张海江,霍鸣,董洁玉,等.核心蛋白多糖抑制翼状胬肉成纤维细胞增生的实验研究[J].眼科新进展,2014,34(8):725.[doi:10.13389/j.cnki.rao.2014.0198]
　ZHANG Hai-Jiang,HUO Ming,DONG Jie-Yu,et al.Inhibitive effects of Decorin on proliferation of cultured human pterygium fibroblasts[J].Recent Advances in Ophthalmology,2014,34(6):725.[doi:10.13389/j.cnki.rao.2014.0198]
[5]郑永征,谢茂松,刘光辉,等.阿那白滞素在治疗大鼠前节内眼模拟手术诱发的血-视网膜屏障破坏中的作用[J].眼科新进展,2020,40(1):016.[doi:10.13389/j.cnki.rao.2020.0004]
　ZHENG Yongzheng,XIE Maosong,LIU Guanghui,et al.Role of Anakinra in alleviating blood retina barrier breakdown induced by anterior intraocular simulation operation in rats[J].Recent Advances in Ophthalmology,2020,40(6):016.[doi:10.13389/j.cnki.rao.2020.0004]
[6]唐磊,徐国彤,张敬法.褪黑素治疗糖尿病视网膜病变的研究进展[J].眼科新进展,2021,41(7):684.[doi:10.13389/j.cnki.rao.2021.0142]
　TANG Lei,XU Guotong,ZHANG Jingfa.Progress of melatonin in the treatment of diabetic retinopathy[J].Recent Advances in Ophthalmology,2021,41(6):684.[doi:10.13389/j.cnki.rao.2021.0142]
[7]刘自强,接传红,王建伟,等.糖尿病视网膜病变免疫机制的研究进展[J].眼科新进展,2022,42(2):150.[doi:10.13389/j.cnki.rao.2022.0031]
　LIU Ziqiang,JIE Chuanhong,WANG Jianwei,et al.Research progress in immune mechanisms against diabetic retinopathy[J].Recent Advances in Ophthalmology,2022,42(6):150.[doi:10.13389/j.cnki.rao.2022.0031]

备注/Memo

备注/Memo:
国家自然科学基金资助（编号：81400414、81271031、81600736）
更新日期/Last Update: 2017-06-28